Vorinostat in solid and hematologic malignancies

Keyphrases

• Hematological Malignancies 100%
• Vorinostat 100%
• Solid Malignancies 100%
• Combination Therapy 30%
• Monotherapy 30%
• Drug Adverse Events 30%
• Vomiting 20%
• Diarrhea 20%
• Malignancy 20%
• Nausea 20%
• Systemic Therapy 20%
• Anorexia 20%
• Clinical Trials 10%
• Multiple Myeloma 10%
• Clinical Trial Data 10%
• Non-small Cell Lung Cancer (NSCLC) 10%
• Adverse Events 10%
• Anticancer Activity 10%
• Dehydration 10%
• Thrombocytopenia 10%
• Histone Deacetylase Inhibitor (HDACi) 10%
• Tolerability 10%
• Phase I Trial 10%
• Glioblastoma multiforme 10%
• Recurrent Disease 10%
• U.S. Food 10%
• Platelet Count 10%
• Cutaneous Manifestations 10%
• Progressive Disease 10%
• Cutaneous T-cell Lymphoma 10%
• Myelodysplastic Syndrome 10%

Medicine and Dentistry

• Vorinostat 100%
• Hematologic Malignancy 100%
• Adverse Event 36%
• Combination Therapy 27%
• Monotherapy 27%
• Clinical Trial 18%
• Diarrhea 18%
• Cancer 18%
• Nausea 18%
• Systemic Therapy 18%
• Anorexia 18%
• Multiple Myeloma 9%
• Recurrent Disease 9%
• Antineoplastic Activity 9%
• Non Small Cell Lung Cancer 9%
• Platelet 9%
• Glioblastoma 9%
• Thrombocytopenia 9%
• Histone Deacetylase Inhibitor 9%
• Myelodysplastic Syndrome 9%
• Cutaneous T Cell Lymphoma 9%
• Phase I Trials 9%
• Progressive Disease 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Vorinostat 100%
• Hematologic Malignancy 100%
• Adverse Event 36%
• Combination Therapy 27%
• Monotherapy 27%
• Clinical Trial 18%
• Nausea 18%
• Diarrhea 18%
• Anorexia 18%
• Multiple Myeloma 9%
• Non Small Cell Lung Cancer 9%
• Thrombocytopenia 9%
• Phase I Trials 9%
• Tolerability 9%
• Glioblastoma 9%
• Recurrent Disease 9%
• Histone Deacetylase Inhibitor 9%
• Myelodysplastic Syndrome 9%
• Cutaneous T Cell Lymphoma 9%